Silicone elastomer formulations for improved performance of a multipurpose vaginal ring releasing dapivirine and levonorgestrel
© 2021 The Author(s)..
A dapivirine-releasing silicone elastomer vaginal ring for reducing women's risk of HIV acquisition has recently been approved. A next-generation multipurpose vaginal ring releasing dapivirine and levonorgestrel is currently in development, offering hormonal contraception and HIV prevention from a single device. Previously, we reported challenges with incorporating levonorgestrel into rings manufactured from addition-cure silicone elastomers due to an irreversible chemical reaction between the levonorgestrel molecule and the hydride-functionalised crosslinker component of the silicone elastomer formulation, leading to low drug content assay, cure inhibition, and reduced ring mechanical properties (which may account for the increased incidence of ring expulsion in vivo). Here, we report on the development and testing of various custom silicone elastomer materials specifically formulated to circumvent these issues. After extensive testing of the custom silicones and subsequent manufacture and testing (Shore M hardness, pot life, content assay, oscillatory rheology, mechanical testing) of rings containing both dapivirine and levonorgestrel, a lead candidate formulation was selected that was amenable to practical ring manufacture via injection molding, exhibited no substantial levonorgestrel binding, and offered suitable mechanical properties.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:3 |
---|---|
Enthalten in: |
International journal of pharmaceutics: X - 3(2021) vom: 21. Dez., Seite 100091 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Dallal Bashi, Yahya H [VerfasserIn] |
---|
Links: |
---|
Themen: |
HIV microbicide |
---|
Anmerkungen: |
Date Revised 04.01.2022 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
---|
doi: |
10.1016/j.ijpx.2021.100091 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM335130402 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM335130402 | ||
003 | DE-627 | ||
005 | 20231225225149.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/j.ijpx.2021.100091 |2 doi | |
028 | 5 | 2 | |a pubmed24n1117.xml |
035 | |a (DE-627)NLM335130402 | ||
035 | |a (NLM)34977558 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Dallal Bashi, Yahya H |e verfasserin |4 aut | |
245 | 1 | 0 | |a Silicone elastomer formulations for improved performance of a multipurpose vaginal ring releasing dapivirine and levonorgestrel |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Revised 04.01.2022 | ||
500 | |a published: Electronic-eCollection | ||
500 | |a Citation Status PubMed-not-MEDLINE | ||
520 | |a © 2021 The Author(s). | ||
520 | |a A dapivirine-releasing silicone elastomer vaginal ring for reducing women's risk of HIV acquisition has recently been approved. A next-generation multipurpose vaginal ring releasing dapivirine and levonorgestrel is currently in development, offering hormonal contraception and HIV prevention from a single device. Previously, we reported challenges with incorporating levonorgestrel into rings manufactured from addition-cure silicone elastomers due to an irreversible chemical reaction between the levonorgestrel molecule and the hydride-functionalised crosslinker component of the silicone elastomer formulation, leading to low drug content assay, cure inhibition, and reduced ring mechanical properties (which may account for the increased incidence of ring expulsion in vivo). Here, we report on the development and testing of various custom silicone elastomer materials specifically formulated to circumvent these issues. After extensive testing of the custom silicones and subsequent manufacture and testing (Shore M hardness, pot life, content assay, oscillatory rheology, mechanical testing) of rings containing both dapivirine and levonorgestrel, a lead candidate formulation was selected that was amenable to practical ring manufacture via injection molding, exhibited no substantial levonorgestrel binding, and offered suitable mechanical properties | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a HIV microbicide | |
650 | 4 | |a Hormonal contraception | |
650 | 4 | |a Mechanical properties | |
650 | 4 | |a Multipurpose prevention technology (MPT) | |
650 | 4 | |a Rheology | |
650 | 4 | |a Silicone elastomer | |
650 | 4 | |a Vaginal rings | |
700 | 1 | |a Murphy, Diarmaid J |e verfasserin |4 aut | |
700 | 1 | |a McCoy, Clare F |e verfasserin |4 aut | |
700 | 1 | |a Boyd, Peter |e verfasserin |4 aut | |
700 | 1 | |a Brown, Leeanne |e verfasserin |4 aut | |
700 | 1 | |a Kihara, Matthew |e verfasserin |4 aut | |
700 | 1 | |a Martin, François |e verfasserin |4 aut | |
700 | 1 | |a McMullen, Nicole |e verfasserin |4 aut | |
700 | 1 | |a Kleinbeck, Kyle |e verfasserin |4 aut | |
700 | 1 | |a Dangi, Bindi |e verfasserin |4 aut | |
700 | 1 | |a Spence, Patrick |e verfasserin |4 aut | |
700 | 1 | |a Hansraj, Bashir |e verfasserin |4 aut | |
700 | 1 | |a Devlin, Brid |e verfasserin |4 aut | |
700 | 1 | |a Malcolm, R Karl |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t International journal of pharmaceutics: X |d 2019 |g 3(2021) vom: 21. Dez., Seite 100091 |w (DE-627)NLM301258015 |x 2590-1567 |7 nnns |
773 | 1 | 8 | |g volume:3 |g year:2021 |g day:21 |g month:12 |g pages:100091 |
856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ijpx.2021.100091 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 3 |j 2021 |b 21 |c 12 |h 100091 |